GLPGF -- USA Stock  

USD 185.00  0.00  0.00%

Mr. Onno van de Stolpe has served as Chief Executive Officer, Executive Director, Chairman of the Executive Committee of Galapagos NV since June 1999. He founded Galapagos in 1999 while he was Managing Director Genomics at Introgene . Prior to joining Introgene in 1998, he was Managing Director of Molecular Probes Europe. He established this European headquarters after joining Molecular Probes in the United States. Previously, he worked for the Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotech and medical device companies to locate in the Netherlands. Mr. van de Stolpe started his career as Manager Business Development at MOGEN in Leiden. He has previously served as member of the supervisory board of the Stichting Institute for Human Organ and Disease Model Technologies and as a member of the board of directors of DCPrime B.V
Age: 58  CEO Since 1999      
32 1 534 29 00  http://www.glpg.com
Onno van de Stolpe received a MS degree from the Agricultural in Wageningen.

Management Efficiency

The company has return on total asset (ROA) of 6.84 % which means that it generated profit of $6.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 15.06 % meaning that it generated $15.06 on every $100 dollars invested by stockholders.

Similar Executives

Found 9 records

CEO Since

Satya NadellaMicrosoft Corporation
Charles ScharfVisa
Yong ZhangAlibaba Group Holding Limited
Timothy CookApple
Charlotte HoggVisa
Larry PageAlphabet
Tim CookApple
Sundar PichaiAlphabet
Zhaoxi LuAlibaba Group Holding Limited

Entity Summary

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company was founded in 1999 and is headquartered in Mechelen, Belgium. GALAPAGOS is traded on BATS Exchange in USA.GALAPAGOS NV [GLPGF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

GALAPAGOS NV Leadership Team

Rajesh Parekh, Non-Executive Chairman of the Board
Andre Hoekema, Sr. VP of Corporate Devel.
Katrine Bosley, Independent Non-Executive Director
Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer
Howard Rowe, Non-Executive Independent Director
Bob Rajan, Non-Executive Independent Director
Harrold Barlingen, Non-Executive Director
Raj Parekh, Non-Executive Chairman of the Board
Elizabeth Goodwin, VP Corporate Communications & Investor Relations
Mary Kerr, Non-Executive Independent Director
Piet Wigerinck, Chief Scientific Officer
Bart Filius, CFO
Christine Mummery, Non-Executive Independent Director
Werner Cautreels, Non-Executive Independent Director
Onno Stolpe, Co-Founder, CEO, Managing Director and Executive Director

Stock Performance Indicators

Current Sentiment - GLPGF

GALAPAGOS NV Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in GALAPAGOS NV. What is your judgment towards investing in GALAPAGOS NV? Are you bullish or bearish?
50% Bullish
50% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Market Hitters module to find equities that experience drastic asymmetry in trading patters, price, volume, or investment outlook..
Search macroaxis.com